# Protease Inhibitors and Innate Immune Agonists as Antiviral Strategies Against Dengue and Zika Viruses

## TL;DR

This paper reviews antiviral strategies against Dengue and Zika viruses, focusing on protease inhibitors and immune system boosters.

## Contribution

The paper provides a comprehensive review of both protease inhibition and innate immune agonist approaches for antiviral therapies.

## Key findings

- Covalent and non-covalent protease inhibitors effectively suppress flavivirus replication.
- Agonists of TLRs, RIG-I, and cGAS–STING enhance antiviral defenses by boosting interferon production.
- Combining these strategies may lead to next-generation therapies for Dengue and Zika.

## Abstract

Emerging mosquito-borne flaviviruses, such as Dengue virus (DENV) and Zika virus (ZIKV), pose major global public health threats due to their geographic expansion, climate change, and the absence of effective antiviral therapies. Antiviral development against these pathogens has primarily focused on two complementary strategies. On the one hand, the blocking of viral replication by directly inhibiting essential viral enzymes, and on the other, enhancing the host’s innate immune defenses via targeted activation of intracellular antiviral pathways. Among the viral proteins required for replication, the NS2B–NS3 protease complex is one of the most conserved and druggable targets, prompting extensive efforts to design both covalent and non-covalent inhibitors. Covalent inhibitors, such as boronic acids, aldehydes, trifluoromethyl ketones, phenoxymethylphenyl derivatives, and α-ketoamides, form irreversible or slowly reversible bonds with the catalytic serine residue (Ser 135), producing long-lasting and high-affinity suppression of protease activity. In parallel, several classes of non-covalent, particularly allosteric, inhibitors have emerged as promising alternatives with improved specificity and reduced off-target reactivity. A complementary antiviral strategy involves the use of agonists of key innate immune sensors such as TLRs, RIG-I, and the cGAS–STING axis, which mediate the release of interferons (IFNs). This review brings together current knowledge on these two mechanistically distinct yet convergent approaches, highlighting how both can ultimately restrict flavivirus replication. Future opportunities involving modified peptide scaffolds, advanced delivery systems, and drug-repurposing strategies are finally discussed for the development of next-generation therapeutics against DENV and ZIKV.